The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Levo Therapeutics’ LV-101 (intranasal carbetocin) for the treatment of Prader-Willi syndrome (PWS). Presently the biotech venture is sponsoring a Phase III clinical study of intranasal...
Dr. Susan Manzi, MD, MPH, with Allegheny Health Network, an internationally known lupus clinical researcher and investigator, was selected for the 2019 Distinguished Clinical Investigator Award by the American College of Rheumatology. Dr. Manzi is among an elite group...
An important study led by Australian researchers from the Walter and Eliza Hall Institute in Melbourne and colleagues discovered in laboratory models that strong inflammatory signals caused by malaria infection activate molecules that trigger the production of highly...
A Mayo Clinic-led study centering on 3,276 patients discovered that people with inflammatory bowel disease, Type 1 diabetes or blood clots may face higher risks for developing rheumatoid arthritis and rheumatoid arthritis patients face risk of developing heart...
X4 Pharmaceuticals announced the U.S. FDA has granted Breakthrough Therapy Designation for mavorixafor (X4P-001) for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome. A Breakthrough Therapy Designation...
Dr. Richard Furie, with Northwell Health’s The Feinstein Institutes for Medical Research, will publish and present data describing the clinical benefit of anifrolumab for patients with lupus in Lancet Rheumatology and at the American College of Rheumatology’s Annual...
